ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc (CYCN)

2.87
0.18
(6.69%)
At close: June 24 4:00PM
2.87
0.00
( 0.00% )
After Hours: 7:03PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
2.87
Bid
2.35
Ask
2.90
Volume
12,065
2.50 Day's Range 2.9199
1.7501 52 Week Range 5.25
Market Cap
Previous Close
2.69
Open
2.75
Last Trade
5
@
2.5
Last Trade Time
18:04:03
Financial Volume
$ 32,670
VWAP
2.7078
Average Volume (3m)
2,979
Shares Outstanding
2,710,096
Dividend Yield
-
PE Ratio
-1.48
Earnings Per Share (EPS)
-1.94
Revenue
-
Net Profit
-5.26M

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of nex... Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Boston, Massachusetts, USA
Founded
1970
Cyclerion Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CYCN. The last closing price for Cyclerion Therapeutics was $2.69. Over the last year, Cyclerion Therapeutics shares have traded in a share price range of $ 1.7501 to $ 5.25.

Cyclerion Therapeutics currently has 2,710,096 shares outstanding. The market capitalization of Cyclerion Therapeutics is $7.78 million. Cyclerion Therapeutics has a price to earnings ratio (PE ratio) of -1.48.

CYCN Latest News

Cyclerion Appoints Regina Graul, Ph.D., as President

– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.134.744525547452.743.091.9176972.43945843CS
4-0.09-3.040540540542.963.091.951862.44947247CS
12-0.45-13.55421686753.323.981.929792.75070223CS
26-1.27-30.67632850244.144.321.930533.0745789CS
52-1.5-34.32494279184.375.251.750163453.414141CS
156-73.73-96.253263707676.684.61.750118793635.90383512CS
260-222.33-98.7255772647225.2296.61.750133977363.16340423CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GLYCGlycoMimetics Inc
$ 0.4396
(64.89%)
25.86M
SNTISenti Biosciences Inc
$ 0.3803
(50.91%)
9.77M
LGHLWLion Group Holding Ltd
$ 0.0094
(38.24%)
100
VLCNVolcon Inc
$ 5.20
(34.02%)
140.57k
ODPODP Corporation
$ 47.52
(21.85%)
8.19k
MLGOMicroAlgo Inc
$ 10.25
(-31.67%)
5.17M
XAIRBeyond Air Inc
$ 0.99
(-26.12%)
525.65k
FFIEFaraday Future Intelligent Electric Inc
$ 0.2449
(-24.88%)
11.6M
HGASGlobal Gas Corporation
$ 0.7416
(-24.33%)
68.1k
LIPOLipella Pharmaceuticals Inc
$ 0.53
(-16.14%)
313.68k
GLYCGlycoMimetics Inc
$ 0.4396
(64.89%)
25.86M
NVDANVIDIA Corporation
$ 116.949
(-0.98%)
17.02M
FFIEFaraday Future Intelligent Electric Inc
$ 0.2449
(-24.88%)
11.6M
SNTISenti Biosciences Inc
$ 0.3803
(50.91%)
9.77M
CRKNCrown Electrokinetics Corporation
$ 0.0364
(-4.96%)
9.17M

CYCN Discussion

View Posts
dinogreeves dinogreeves 1 year ago
CYCN with big volume could run to the teens.
👍️0
dinogreeves dinogreeves 1 year ago
Boombaska.
👍️0
dinogreeves dinogreeves 1 year ago
One heck of a run coming here fairly soon. Buy the dip and enjoy the rip. CEO paid $8.50 for shares here.
👍️0
Invest-in-America Invest-in-America 1 year ago
CYCN: Hey, & "Little Debbie" is still alive and well!! (See her below!! However, NOT quite as 'cute' as she used to be, though.)



👍️0
subslover subslover 1 year ago
LMAO. You're still partying from Friday night. I know a few peps that need your stuff! :)
👍️0
Invest-in-America Invest-in-America 1 year ago
CYCN: Get ready to PARTY!!! My glorious CYCN HomeBoys, HomeGirls, & straight-up GangBangers!!! I gots the party MUSIC for ya-all, below!!! Who's gonna bring the REFRESHMENTS!!!??? (Hey, Admiral S-L, how about some disruptive, brand-new, very tasty, "Little-Debbie-Cannabis-Infused-Strawberry-Snack-Cakes", Dude!!!???)

👍️0
subslover subslover 1 year ago
Cyclerion's zagociguat gets FDA orphan drug status
👍️0
subslover subslover 1 year ago
Cyclerion's zagociguat gets FDA orphan drug status
👍️0
NYCJR NYCJR 2 years ago
funny its a lot more than that now , close to 12x your call, lol
👍️0
willlbone willlbone 2 years ago
45% layoffs. Bid 25 cents.
👍️0
Banjo50 Banjo50 2 years ago
I think it should be 5 cents. I bid 5 cents EACH for 100 shares. Five cents is fair.
👍️0
kzivann kzivann 2 years ago
Bid for some.

CYCN
👍️0
willlbone willlbone 2 years ago
Bounce back and close the gap.
👍️0
Banjo50 Banjo50 2 years ago
IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!
👍️0
Banjo50 Banjo50 2 years ago
IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!
👍️0
ClayTrader ClayTrader 3 years ago
* * $CYCN Video Chart 06-08-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
CYDYWinning CYDYWinning 3 years ago
Anyone know when results are out might drop a few k this week here
👍️0
Ivegotanace2 Ivegotanace2 3 years ago
BOUNCE $$$$$
👍️0
bcnuby1 bcnuby1 3 years ago
Nice breakout this evening. glta
👍️0
bcnuby1 bcnuby1 3 years ago
Going UP. glta
👍️0
Dubster watching Dubster watching 4 years ago
Recent charts steadily improving
👍️0
Dubster watching Dubster watching 4 years ago
Up nicely today!!
👍️0
Banski Banski 4 years ago
This stock is getting painful.
👍️0
Dubster watching Dubster watching 4 years ago
Talk about oversold.
👍️0
ClayTrader ClayTrader 4 years ago
* * $CYCN Video Chart 03-23-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
dude iligence dude iligence 4 years ago
CYCN $4.5s revisited steadly moving higher as volume increases. CYCN has explosive breakouts. The last one CYCN ran up to $6.25ish 49% in one day closing as biggest gainer on Nasdaq that day. CYCN been trading in a upward channel bouncing off the trend line. It held up very well last week in the market downdraft. The next leg should punch above the 200ma. How high we wont put a target on it just let it run. It should breakout above $4.83-$4.85ish.


In the time of this post pps now $4.61
👍️0
ClayTrader ClayTrader 4 years ago
* * $CYCN Video Chart 02-19-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
dude iligence dude iligence 4 years ago
CYCN $5s +25% stairstepping toward the 200ma $8s just broke out above $4.7 then blew north of $5 while I was preparing a post





👍️0
ClayTrader ClayTrader 4 years ago
* * $CYCN Video Chart 02-05-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
NotRichYet2 NotRichYet2 4 years ago
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announces positive Phase 1 study results that provide the foundation for continued development of IW-6463, an oral, once-daily central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of serious neurodegenerative diseases. The nitric oxide pathway and sGC stimulation have long been known to be a central physiological regulator in the central nervous system, impacting cerebrovascular blood flow, neuroinflammation, neuronal function and metabolism.
“Our Phase 1 healthy volunteer study results indicate that IW-6463 was well tolerated. Pharmacokinetic (PK) data, obtained from both blood and cerebral spinal fluid (CSF), support once-daily dosing with or without food and demonstrate IW-6463 penetration across the blood-brain-barrier at levels expected to be pharmacologically active. We are excited about the therapeutic possibilities for IW-6463 as a first-in-class, brain penetrant sGC stimulator,” said Chris Wright, M.D., Chief Medical Officer of Cyclerion. “These results, together with our preclinical data, provide strong support for continued development of IW-6463 as a potential new medicine for serious neurodegenerative diseases.”

Phase 1 Study Design and Topline Results

The company’s first IW-6463 Phase 1 study was conducted in 110 healthy volunteers aged 18-63 years to evaluate safety and pharmacokinetics in blood and CSF. The three-stage study evaluated: a) single ascending doses, b) multiple ascending doses (over 14 days) and c) food interaction effects. Study results demonstrated that IW-6463 was well tolerated across the tested dose levels. The most common adverse events (AEs) observed in the active treatment group were headache, nausea, dizziness, somnolence and fatigue. All AEs were mild and no serious adverse events (SAEs) were observed. IW-6463 administration resulted in a mild reduction in blood pressure, a known characteristic of sGC stimulators, providing evidence of peripheral pharmacological activity and target engagement. PK data obtained from the CSF demonstrate penetration of IW-6463 into the CNS at levels expected to be pharmacologically active. Food interaction results indicate that IW-6463 may be taken with or without food. These data, together with plasma PK results, support development of IW-6463 as a once-daily orally administered therapeutic.

Ongoing and Planned Development Activities

A translational pharmacology study in approximately 24 elderly subjects is ongoing. This study will evaluate safety, PK, and measures of CNS pharmacological activity, including cerebral blood flow by MRI and additional translational measures. Topline study results are expected in mid-2020. These results are intended to enable Cyclerion to direct further development in high-value CNS indications where biological and genetic data suggest an important role for nitric oxide and cyclic guanosine monophosphate (cGMP) signaling.

Presentation at J.P. Morgan Healthcare Conference

Cyclerion will discuss IW-6463 and its CNS program, along with its diabetic nephropathy and sickle cell disease clinical programs, at the J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020. The presentation will be webcast at 9:00AM PST (12:00PM EST). Note that the webcast presentation EST time was incorrect on the company’s December 23, 2019 webcast press release announcement, and the correct time is 12:00PM EST.

The presentation will be followed by a question and answer session to be held at 9:30AM PT (12:30PM EST). A live webcast of the presentation and the Q&A session can be accessed on the following links:

Presentation link:
https://jpmorgan.metameetings.net/events/hc20/sessions/29869-cyclerion/webcast

Q&A link:
https://jpmorgan.metameetings.net/events/hc20/sessions/30203-cyclerion-q-a/webcast

A replay of the presentation will be posted on the Cyclerion website following the event.

About IW-6463

IW-6463, a CNS-penetrant sGC stimulator, is being developed as a potentially disease modifying therapy for neurodegenerative diseases. Nitric oxide is one of several fundamental neurotransmitters, one that has yet to be leveraged for its therapeutic potential in the CNS. sGC stimulators work synergistically with the nitric oxide naturally produced in the body to boost the positive effects of nitric oxide, even when the body is not producing enough. There are clear links between nitric oxide signaling defects and neurodegenerative diseases. Evidence indicates that endothelial cell loss and nitric oxide dysregulation are contributors to neurodegenerative diseases and result in reduced blood flow, vascular leakage, inflammation, and neuronal dysfunction/loss. sGC is expressed widely throughout the CNS and CNS vasculature. In preclinical studies, IW-6463 has been associated with increased cerebral blood flow, reduced markers of neuroinflammation, improved neuronal health, neuroprotective effects and enhanced cellular bioenergetics and mitochondrial function.

About Cyclerion Therapeutics

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs include praliciguat which recently completed Phase 2 studies and which the company intends to out-license for further development in diabetic nephropathy, olinciguat in Phase 2 development for sickle cell disease, IW-6463 in Phase 1 development for serious CNS diseases, and two preclinical programs targeting serious liver and lung diseases, respectively.

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

Forward Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements about the anticipated timing of release of topline results of our clinical trials; the progression of our discovery programs into clinical development; and the business and operations of Cyclerion. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to our ability to obtain necessary approvals from regulatory authorities; our ability to advance product candidates in clinical trials; that regulatory approval processes are lengthy, time-consuming and inherently unpredictable; that significant variability in safety or efficacy may appear in different clinical studies of the same product candidate; that product candidates in later stages of clinical studies often fail to demonstrate adequate safety and efficacy despite promising preclinical testing and earlier clinical studies; the timing, investment and associated activities involved in developing and obtaining regulatory approval for our product candidates; our plans with respect to the development of our product candidates and the associated timing thereof, including the design and results of pre-clinical and clinical studies; the efficacy of our product candidates; and the risks more fully listed under the heading “Risk Factors” and elsewhere in our Registration Statement on Form 10 filed on March 11, 2019, and in Cyclerion’s subsequent SEC filings, including the Form 10-Q filed on November 12, 2019. Investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Cyclerion undertakes no obligation to update these forward-looking statements, except as required by law.

Contact

Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
👍️0
dude iligence dude iligence 4 years ago
CYCN $3.05 chart huge potential How Big HUGE! 200ma $9.85



IPO s that pullback and settle out consolidate then start climbing make great trades/investments. Phara is red hot right now CYCN could be a gap closer all the way up then keep going.



👍️0
Actualfactual Actualfactual 4 years ago
Broke resistance at $3. Huge gap coming up from around $3.60 to $8
👍️0
interloper interloper 5 years ago
CYCN


5 min chart with Bollie pinch breakout
👍️0
ClayTrader ClayTrader 5 years ago
* * $CYCN Video Chart 12-16-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $CYCN Video Chart 11-19-19 * *

Link to Video - click here to watch the technical chart video

👍️0
adtime adtime 5 years ago
In some at eod.. from 14+ to under 2 severely oversold
👍️0
TeddyCaswell TeddyCaswell 5 years ago
My birthday
👍️0
braddddd braddddd 5 years ago
board created 10/30/2019
👍️0

Your Recent History

Delayed Upgrade Clock